Clinical trial
Blood Markers of Early Pancreas Cancer
NCT03568630
Drugs and interventions used in this trial
0 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No interventions are currently published for this study in CureCurrent. View the original registry record below.
Study at a glance
Registry-backedBlood Markers of Early Pancreas Cancer
Design: OBSERVATIONAL · Status: RECRUITING · Phase: Not specified
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
PreDiabetesverified · MONDO: prediabetes syndrome
Pancreas Cystunresolved
Genetic Predisposition to Diseaseunresolved
Inherited Diseaseverified · MONDO: hereditary disease
Interventions
Sponsors & collaborators
University of Nebraskalead sponsor
National Cancer Institute (NCI)collaborator
Virginia Mason Hospital/Medical Centercollaborator
VA Nebraska Western Iowa Health Care Systemcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03568630 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.